Winfried Wels

University Name

Research Interests

Explore related searches

Contact this professor

Google Scholar

Articles (22)

Collaborators (10)

Venugopal Gudipati

Medical University of Vienna

Christian Buchholz

Paul-Ehrlich-Institut

Sabrina B. Bennstein

Sachin G. Thakkar

Baylor College of Medicine

UNITED STATES

Heiko Rühl

University Hospital Bonn

Johannes Huppa

Medical University of Vienna

Shoba Navai

Assistant Professor

Baylor College of Medicine Department of Pediatrics

UNITED STATES

Michael Rieger

Assistant Professor (W2)

Adelheid Cerwenka

M.C. Burger

Goethe University Frankfurt

Winfried Wels

Research Interests

Explore related searches

Contact this professor

Articles (22)

Collaborators (10)

Venugopal Gudipati

Christian Buchholz

Sabrina B. Bennstein

Sachin G. Thakkar

Heiko Rühl

Johannes Huppa

Shoba Navai

Michael Rieger

Adelheid Cerwenka

M.C. Burger

How do I reach out?

Meet Kite AI

Winfried Wels

Research Interests

Explore related searches

Contact this professor

Articles (22)

CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma

Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells

ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial

Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy

Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies

Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors

Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma

Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD<sub>2</sub>-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2

Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity

Innate-like NKp30+CD8+ T cells armed with TCR/CAR target tumor heterogeneity

Innate-like NKp30+CD8+ T cells armed with TCR/CAR target tumor heterogeneity

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.

Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells.

Collaborators (10)

Venugopal Gudipati

Christian Buchholz

Sabrina B. Bennstein

Sachin G. Thakkar

Heiko Rühl

Johannes Huppa

Shoba Navai

Michael Rieger

Adelheid Cerwenka

M.C. Burger

How do I reach out?

Meet Kite AI